期刊
ANTIVIRAL RESEARCH
卷 185, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2020.104995
关键词
Hepatitis D virus; Meta-analysis; Randomized clinical trials; Biochemical response; Virologic response
The study shows that peginterferon has limited effectiveness in the treatment of chronic HDV, with only one-third of patients achieving viral clearance and normalization of ALT levels. Furthermore, HBsAg clearance with seroconversion to anti-HBs is rarely observed among chronic HDV patients.
Chronic HDV infection often is associated with aggressive form of liver disease, compared to chronic HBV monoinfection. However, chronic HDV treatment is challenging because currently there is no approved regimen for affected patients. While standard interferon with/without nucleos(t)ide analogues were reported to be inferior to pegylated interferon (peginterferon) as HDV treatment according to few randomized clinical trials. This metaanalysis will summarize the results of studies on the effectiveness of peginterfemn as HDV treatment regimen. An electronic search was performed using PubMed, Cochrane Library, Research Gate, and Medline databases. Studies involving patients who received peginterferon therapy for at least 48 weeks and followed up for 24 weeks post-therapy were included. All analyses were conducted using Review Manager 5.3 designed for Cochrane Reviews. The primary efficacy endpoint was virological response (VR) or HDV-RNA negativity at the end of the follow-up period, whereas secondary efficacy endpoints were biochemical response (BR) or ALT normalization and HBsAg clearance with seroconversion to anti-HBs at the end of follow-up period. Data were abstracted from 13 relevant studies with a total of 475 patients who were treated with peginterfemn alpha-2a or -2b. At the end of 24-week post-treatment the pooled VR was achieved in 29% of patients with 95% CI [24%; 34%], BR was reached in 33% of patients [95% CI 27%; 40%] and HBsAg clearance with seroconversion to anti-HBs was achieved in 1% of patients with 95% CI [-0.02; 0.05]. In conclusion, this study showed that peginterfemn has limited effectiveness in HDV treatment, since only one-third of chronic HDV patients achieved viral clearance and normalized ALT levels. Morever, HBsAg clearance with seroconversion to anti-HBs has been rarely observed among chronic HDV patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据